Trials / Recruiting
RecruitingNCT05895825
A Study of EOC237 in Patients With Advanced Solid Tumor
A Phase I Study Evaluating the Safety, Tolerability and Pharmacokinetics of EOC237 in Patients With Advanced Solid Tumor
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This research study is studying an investigational drug called EOC237 in Patients With Advanced Solid Tumor.
Detailed description
Part 1 Dose Escalation: an open, single/multiple dose, multi-center phase I study to evaluate the safety, tolerability and pharmacokinetics of EOC237 in Patients With Advanced Solid Tumor. Part 2 Food influence research: to assess the effect of food on the pharmacokinetics of EOC237, by investigating the bioavailability following single dose administration under fed and fasted conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EOC237 | EOC237 for orally |
Timeline
- Start date
- 2023-07-26
- Primary completion
- 2026-04-30
- Completion
- 2026-09-30
- First posted
- 2023-06-09
- Last updated
- 2023-11-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05895825. Inclusion in this directory is not an endorsement.